Related Experiment Video
Updated: Jul 10, 2026

New Tools to Expand Regulatory T Cells from HIV-1-infected Individuals
Published on: May 30, 2013
HIV/AIDS vaccines: 2007
1Yerkes National Primate Research Center, Emory Vaccine Center, Emory University School of Medicine, Emory University, Atlanta, Georgia, USA. hrobins@rmy.emory.edu
Abstract:
Development of an HIV/AIDS vaccine has been slow because classical approaches to vaccine development have not yielded a vaccine. Encouragingly, new approaches using recombinant viral vectors, DNA vaccines, and combinations of different vectors in heterologous prime/boost regimens are yielding vaccines capable of controlling virulent immunodeficiency virus challenges in non-human primate models. These new vaccines elicit T cells capable of recognizing and killing virus-infected cells. Brief synopses are given for six vaccines currently advancing in human trials.
More Related Videos
Related Concept Videos
Vaccines
Vaccinations
Cancer Vaccines
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
Retrovirus Life Cycles
Vaccine Production
Sexually Transmitted Infections

